Prime Medicine, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 198.13 million compared to USD 121.82 million a year ago. Basic loss per share from continuing operations was USD 2.18 compared to USD 4.19 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.86 USD | 0.00% | -1.46% | -46.61% |
Apr. 29 | Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance | MT |
Apr. 29 | Prime Medicine Gets FDA Clearance for PM359 IND Application | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.61% | 560M | |
-3.17% | 102B | |
+1.56% | 96.29B | |
+2.13% | 22.18B | |
-15.79% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.75% | 16.36B | |
+5.12% | 13.97B | |
+33.01% | 12.17B |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023